For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
0
views
28
references
 Top references
cited by
0
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      742
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      LncRNA PITPNA-AS1 mediates the diagnostic potential of miR-129-5p in prostate cancer

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          LncRNA has an effective value in many diseases, which has long been applied in the diagnosis, treatment and prognosis of prostate cancer. This study focused on lncRNA PITPNA-AS1, and its diagnostic potential in prostate cancer has been explored.

          Methods

          The expression of PITPNA-AS1 and miR-129-5p in prostate cancer serum and sample cells was determined by real-time quantitative polymerase chain reaction (RT-qPCR). The relationship between the expression of PITPNA-AS1 and clinicopathological parameters was considered. ROC curve prompted the diagnostic value of PITPNA-AS1. The effect of PITPNA-AS1 on prostate cancer cells was verified using vitro cells assay. Luciferase activity assay and RIP assay demonstrated the sponge relationship of PITPNA-AS1 to miR-129-5p.

          Results

          PITPNA-AS1 level was increased, while miR-129-5p was obviously decreased in prostate cancer. PITPNA-AS1 expression was associated with Gleason grade, lymph node metastasis and TNM stage in patients. The area under the curve (AUC) was 0.910, with high sensitivity and specificity. PITPNA-AS1 was elucidated to directly target miR-129-5p, whereas silencing PITPNA-AS1 negatively affected prostate cancer cell proliferation, migration and invasion. Intervention of miR-129-5p inhibitor reversed the effect of silencing PITPNA-AS1 on cells.

          Conclusions

          PITPNA-AS1 was relatively highly expressed in prostate cancer and mediated the pathophysiological process of patients, which may serve as a diagnostic indicator. Silencing of the PITPNA-AS1 sponge miR-129-5p inhibited the biological function of the cells, indicating that PITPNA-AS1 may represent a novel therapeutic target for prostate cancer.

          Supplementary Information

          The online version contains supplementary material available at 10.1186/s12894-024-01528-2.

          Related collections

          Most cited references28

          • Record: found
          • Abstract: found
          • Article: not found

          LncRNA HOXA-AS2 and its molecular mechanisms in human cancer

          Sheng Tai, Shounan Lu, Zhilei Su … (2018)
          Long non-coding RNAs (lncRNAs), a novel class of noncoding RNAs, are commonly defined as RNA molecules more than 200 nucleotides in length. Emerging research indicated that lncRNA played a vital role in human tumorigenesis and progression by serving as tumor oncogenes or suppressors. LncRNA has been shown to get involved in participate various biological processes, such as cell growth, anti-apoptosis, migration and invasion. LncRNA HOXA cluster antisense RNA2 (HOXA-AS2) is a novel cancer-related lncRNA. It was recently found to exhibit aberrant expression in a variety of malignancies, including breast cancer, gastric cancer, gallbladder carcinoma, hepatocellular carcinoma and pancreatic cancer. The oncogenicity of lncRNA HOXA-AS2 mainly inhibits or promotes the expression of related genes through direct or indirect pathways, suggesting that HOXA-AS2 likely represents a feasible biomarker or therapeutic target in human cancers. In this review, we summarize current evidences concerning the biological functions and mechanisms of HOXA-AS2 during tumor development.
          Article 0 comments Cited 124 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found
            Is Open Access

            Role of lncRNA LUCAT1 in cancer

            Ce Xing, Shou-gang Sun, Zhi-Quan Yue … (2021)
            Article 0 comments Cited 118 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              HOTAIR LncRNA: A novel oncogenic propellant in human cancer

              Taruna Rajagopal, Srikanth Talluri, R.L. Akshaya … (2020)
              Long non-coding RNAs (lncRNAs) are an important novel class of non-coding RNAs having lengths of 200 nucleotides and low expression. The HOX Transcript Antisense Intergenic RNA (HOTAIR) is one of the most extensively studied lncRNAs found dysregulated in human cancer. Although a growing body of evidence suggests a role fo HOTAIR in pathogenesis, disease progression, drug resistance and reduced survival, its mechanism of action remains largely unclear. Recent studies have identified that HOTAIR facilitates protein-protein interaction thereby affecting diverse pathways in cancer such as epigenetic reprogramming, protein stability and signal transduction. HOTAIR has been shown to promote tumor progression by regulating microRNA expression and function. Moreover, several HOTAIR gene variants have recently been identified and found to increase cancer susceptibility. Here we review recent data on the critical role of HOTAIR in human malignancy and its potential mechanism of action. A more comprehensive understanding of this unique lncRNA is critical to elucidating the pro-oncogenic function of HOTAIR its potential application in diagnosis, prognosis and treatment.
              Article 0 comments Cited 77 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Contributors
                Qiang Feng: fengqiangdr@163.com
                Chang Wang: Wangchanggz@163.com
                Journal
                Journal ID (nlm-ta): BMC Urol
                Journal ID (iso-abbrev): BMC Urol
                Title: BMC Urology
                Publisher: BioMed Central (London )
                ISSN (Electronic): 1471-2490
                Publication date (Electronic): 13 July 2024
                Publication date PMC-release: 13 July 2024
                Publication date Collection: 2024
                Volume: 24
                Electronic Location Identifier: 146
                Affiliations
                [1 ]Department of Urology Surgery, Jiaozhou Central Hospital of Qingdao, ( https://ror.org/03rzkxc19) Shandong, 266300 China
                [2 ]Medical School of University of Electronic Science and Technology of China, ( https://ror.org/04qr3zq92) Chengdu, 610051 China
                [3 ]GRID grid.410646.1, ISNI 0000 0004 1808 0950, Department of Urinary Surgery, , Sichuan Academy of Medical Sciences, Sichuan Provincial People’s Hospital, ; No. 32, West Section 2, 1st Ring Road, Qingyang District, Chengdu, 610031 China
                [4 ]GRID grid.12981.33, ISNI 0000 0001 2360 039X, Organ Transplant Center, The First Affiliated Hospital, , Sun Yat-sen University, ; No. 58, Zhongshan Second Road, Guangzhou City, 510080 Guangdong Province China
                Article
                Publisher ID: 1528
                DOI: 10.1186/s12894-024-01528-2
                PMC ID: 11245843
                PubMed ID: 39003446
                SO-VID: b36fb9cd-35a5-4147-8bb0-8bc2f8467bb8
                Copyright © © The Author(s) 2024
                License:

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                Date received : 29 December 2023
                Date accepted : 1 July 2024
                Categories
                Subject: Research
                Custom metadata
                issue-copyright-statement © BioMed Central Ltd., part of Springer Nature 2024

                ScienceOpen disciplines: Urology
                Keywords: lncrna pitpna-as1,prostate cancer,mir-129-5p,diagnosis,tumor progression
                Data availability:
                ScienceOpen disciplines: Urology
                Keywords: lncrna pitpna-as1, prostate cancer, mir-129-5p, diagnosis, tumor progression

                Comments

                Comment on this article